Brokerages Set Exact Sciences Corporation (NASDAQ:EXAS) PT at $92.13

Shares of Exact Sciences Corporation (NASDAQ:EXAS) have been assigned a consensus rating of “Reduce” from the twenty-two analysts that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and twenty-one have assigned a hold recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $92.1250.

Several brokerages recently weighed in on EXAS. Evercore set a $105.00 price target on Exact Sciences and gave the company an “in-line” rating in a research report on Monday, January 5th. William Blair cut shares of Exact Sciences from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 20th. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $105.00 target price (up from $85.00) on shares of Exact Sciences in a report on Thursday, November 20th. Stifel Nicolaus reiterated a “hold” rating and issued a $105.00 target price (up from $80.00) on shares of Exact Sciences in a research note on Friday, November 28th. Finally, Mizuho reissued a “neutral” rating and set a $105.00 price target (up from $85.00) on shares of Exact Sciences in a report on Tuesday, January 20th.

Exact Sciences Price Performance

Shares of EXAS opened at $103.57 on Monday. The business’s 50-day moving average is $102.83 and its two-hundred day moving average is $83.60. The company has a market capitalization of $19.77 billion, a P/E ratio of -94.15, a P/E/G ratio of 2.35 and a beta of 1.41. Exact Sciences has a fifty-two week low of $38.81 and a fifty-two week high of $103.75. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.17 and a current ratio of 2.43.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Friday, February 13th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.29). Exact Sciences had a negative net margin of 6.40% and a positive return on equity of 0.53%. During the same period last year, the firm posted ($0.06) earnings per share. The company’s revenue was up 23.1% compared to the same quarter last year. Research analysts predict that Exact Sciences will post -0.58 earnings per share for the current year.

Institutional Investors Weigh In On Exact Sciences

Several hedge funds have recently modified their holdings of EXAS. HBK Investments L P acquired a new stake in shares of Exact Sciences during the 4th quarter valued at about $776,592,000. Pentwater Capital Management LP acquired a new position in Exact Sciences in the 4th quarter worth about $736,310,000. Ameriprise Financial Inc. boosted its position in Exact Sciences by 105.8% during the third quarter. Ameriprise Financial Inc. now owns 4,493,085 shares of the medical research company’s stock worth $245,802,000 after purchasing an additional 2,310,139 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in Exact Sciences by 31.7% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,909,501 shares of the medical research company’s stock worth $213,889,000 after purchasing an additional 939,888 shares in the last quarter. Finally, Norges Bank acquired a new stake in Exact Sciences in the fourth quarter valued at approximately $348,425,000. 88.82% of the stock is owned by hedge funds and other institutional investors.

Exact Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.